Vertex Pharmaceuticals Incorporated: One Eye on Earnings, One on the Pipeline
Vertex Pharmaceuticals (NASDAQ: VRTX) reported solid third-quarter earnings, with sales of its cystic fibrosis drugs up 34% year over year. Nevertheless, investors rightfully have one eye on the company's pipeline, looking for the next drug that will drive future growth. Fortunately, Vertex has a combination under review by U.S. and EU regulators, and is preparing to test a pair of triple combinations that the company thinks will allow it to treat 90% of cystic fibrosis patients.
Metric
Q3 2017
Source: Fool.com
Vertex Pharmaceuticals Inc. Stock
€447.40
0.390%
The stock is one of the favorites of our community with 47 Buy predictions and 2 Sell predictions.
On the other hand, the target price of 428 € is below the current price of 447.4 € for Vertex Pharmaceuticals Inc., so the potential is actually -4.34%.
